Boudes Pol F 4
4 · GALECTIN THERAPEUTICS INC · Filed Mar 16, 2020
Insider Transaction Report
Form 4
Boudes Pol F
Chief Medical Officer
Transactions
- Award
Stock option (right to buy)
2020-03-12+300,000→ 300,000 totalExercise: $1.75Exp: 2030-03-12→ Common Stock (300,000 underlying)
Footnotes (2)
- [F1]The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan.
- [F2]The options vest as follows: (i) 20% on each of March 2, 2021, March 2, 2022, March 2, 2023 and (i) 40% on March 2, 2024.